Liu Wei was re-elected as the executive director of Kangrun Bio-B (06922).

Kangyuan Bio-B (06922) announced that at the annual meeting of shareholders, Li Kejian, Zhu Jun and Liu Wei were re-elected as the second...

Zhitong FinanceJun 14 08:41 ET

Uncover the reason behind Kangfeng Bio-B's (06922) market capitalization shrinking by nearly 70% in 5 months

In fact, since the end of last year, good news on Kang Feng Biotech's fundamentals has been released one after another, but judging from the stock price trend, none of this has impressed investors; on the contrary, it has caused the company's stock price to fall to a low point. What exactly is the reason behind this?

Zhitong FinanceMay 24 07:28 ET

康灃生物-B：2023年年報

Hong Kong Stock ExchangeApr 25 06:36 ET · Announcements

Cryofocus Medtech (Shanghai) Co., Ltd.'s (HKG:6922) Market Cap Surged HK$471m Last Week, Private Companies Who Have a Lot Riding on the Company Were Rewarded

Key Insights The considerable ownership by private companies in Cryofocus Medtech (Shanghai) indicates that they collectively have a greater say in management and business strategy The top 3 shareho

Simply Wall StApr 8 19:24 ET

Kang Feng Bio-B: The Stock Exchange granted listing approval to implement full circulation of H shares

Kang Feng Bio-B (06922) announced that the company has applied to the Stock Exchange Listing Committee for approval (listing approval) of 29.342 million H shares (conversion of H shares) of the company, that is, the maximum number of unlisted shares (unlisted shares) of the company to be converted under conversion and listing, listing and trading. The Company is pleased to announce that on April 3, 2024, the Stock Exchange has granted listing approval, which is subject to all other conditions for conversion and listing before it can be implemented.

新浪港股Apr 4 20:12 ET

Kang Feng Bio-B (06922.HK): The Stock Exchange granted listing approval to implement full circulation of H shares

Gelonghui, April 3 | Kang Feng Bio-B (06922.HK) announced that the company has applied to the Stock Exchange Listing Committee to approve 29,341,981 H shares of the company, that is, the maximum number of unlisted shares of the company to be converted, listed and traded under the conversion and listing. The Company is pleased to announce that on April 3, 2024, the Stock Exchange has granted listing approval, which is subject to all other conditions for conversion and listing before it can be implemented.

Gelonghui FinanceApr 3 07:33 ET